Cargando…
Neuropsychiatric Disorders and COVID-19: What We Know So Far
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) affects the central nervous system (CNS), which is shown in a significant number of patients with neurological events. In this study, an updated literature review was carried out regarding neurological disorders in COVID-19. Neurological s...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465079/ https://www.ncbi.nlm.nih.gov/pubmed/34577633 http://dx.doi.org/10.3390/ph14090933 |
_version_ | 1784572779642748928 |
---|---|
author | Majolo, Fernanda da Silva, Guilherme Liberato Vieira, Lucas Anli, Cetin Timmers, Luís Fernando Saraiva Macedo Laufer, Stefan Goettert, Márcia Inês |
author_facet | Majolo, Fernanda da Silva, Guilherme Liberato Vieira, Lucas Anli, Cetin Timmers, Luís Fernando Saraiva Macedo Laufer, Stefan Goettert, Márcia Inês |
author_sort | Majolo, Fernanda |
collection | PubMed |
description | SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) affects the central nervous system (CNS), which is shown in a significant number of patients with neurological events. In this study, an updated literature review was carried out regarding neurological disorders in COVID-19. Neurological symptoms are more common in patients with severe infection according to their respiratory status and divided into three categories: (1) CNS manifestations; (2) cranial and peripheral nervous system manifestations; and (3) skeletal muscle injury manifestations. Patients with pre-existing cerebrovascular disease are at a higher risk of admission to the intensive care unit (ICU) and mortality. The neurological manifestations associated with COVID-19 are of great importance, but when life-threatening abnormal vital signs occur in severely ill COVID-19 patients, neurological problems are usually not considered. It is crucial to search for new treatments for brain damage, as well as for alternative therapies that recover the damaged brain and reduce the inflammatory response and its consequences for other organs. In addition, there is a need to diagnose these manifestations as early as possible to limit long-term consequences. Therefore, much research is needed to explain the involvement of SARS-CoV-2 causing these neurological symptoms because scientists know zero about it. |
format | Online Article Text |
id | pubmed-8465079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84650792021-09-27 Neuropsychiatric Disorders and COVID-19: What We Know So Far Majolo, Fernanda da Silva, Guilherme Liberato Vieira, Lucas Anli, Cetin Timmers, Luís Fernando Saraiva Macedo Laufer, Stefan Goettert, Márcia Inês Pharmaceuticals (Basel) Review SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) affects the central nervous system (CNS), which is shown in a significant number of patients with neurological events. In this study, an updated literature review was carried out regarding neurological disorders in COVID-19. Neurological symptoms are more common in patients with severe infection according to their respiratory status and divided into three categories: (1) CNS manifestations; (2) cranial and peripheral nervous system manifestations; and (3) skeletal muscle injury manifestations. Patients with pre-existing cerebrovascular disease are at a higher risk of admission to the intensive care unit (ICU) and mortality. The neurological manifestations associated with COVID-19 are of great importance, but when life-threatening abnormal vital signs occur in severely ill COVID-19 patients, neurological problems are usually not considered. It is crucial to search for new treatments for brain damage, as well as for alternative therapies that recover the damaged brain and reduce the inflammatory response and its consequences for other organs. In addition, there is a need to diagnose these manifestations as early as possible to limit long-term consequences. Therefore, much research is needed to explain the involvement of SARS-CoV-2 causing these neurological symptoms because scientists know zero about it. MDPI 2021-09-17 /pmc/articles/PMC8465079/ /pubmed/34577633 http://dx.doi.org/10.3390/ph14090933 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Majolo, Fernanda da Silva, Guilherme Liberato Vieira, Lucas Anli, Cetin Timmers, Luís Fernando Saraiva Macedo Laufer, Stefan Goettert, Márcia Inês Neuropsychiatric Disorders and COVID-19: What We Know So Far |
title | Neuropsychiatric Disorders and COVID-19: What We Know So Far |
title_full | Neuropsychiatric Disorders and COVID-19: What We Know So Far |
title_fullStr | Neuropsychiatric Disorders and COVID-19: What We Know So Far |
title_full_unstemmed | Neuropsychiatric Disorders and COVID-19: What We Know So Far |
title_short | Neuropsychiatric Disorders and COVID-19: What We Know So Far |
title_sort | neuropsychiatric disorders and covid-19: what we know so far |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465079/ https://www.ncbi.nlm.nih.gov/pubmed/34577633 http://dx.doi.org/10.3390/ph14090933 |
work_keys_str_mv | AT majolofernanda neuropsychiatricdisordersandcovid19whatweknowsofar AT dasilvaguilhermeliberato neuropsychiatricdisordersandcovid19whatweknowsofar AT vieiralucas neuropsychiatricdisordersandcovid19whatweknowsofar AT anlicetin neuropsychiatricdisordersandcovid19whatweknowsofar AT timmersluisfernandosaraivamacedo neuropsychiatricdisordersandcovid19whatweknowsofar AT lauferstefan neuropsychiatricdisordersandcovid19whatweknowsofar AT goettertmarciaines neuropsychiatricdisordersandcovid19whatweknowsofar |